Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Natalizumab effects on immune cell responses in multiple sclerosis.

Masaaki Niino1, Caroline Bodner, Marie-Lune Simard

  • 1Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Quebec, Canada.

Annals of Neurology
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal B-Cell Exosome Proapoptotic and Antiapoptotic Cargo in Multiple Sclerosis: Potential Implication in Progressive Disease Biology.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics.

The Lancet. Neurology·2026
Same author

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.

European journal of neurology·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

The Effect of Ocrelizumab on Anti-JC Virus Antibody Index.

Brain and behavior·2026
Same author

The gut microbiome in pediatric-onset acquired demyelinating syndromes by myelin oligodendrocyte glycoprotein antibody status.

Multiple sclerosis and related disorders·2026

Natalizumab partially reduces immune cell migration in multiple sclerosis (MS) patients by diminishing VLA-4 expression. Effects vary between patients and are not sustained throughout the monthly dosing interval.

Area of Science:

  • Immunology
  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system.
  • Natalizumab is an antibody used to treat MS by targeting immune cell trafficking.

Purpose of the Study:

  • To investigate the in vivo biological effects of natalizumab on immune cell phenotype and function in MS patients.
  • To assess changes in VLA-4 expression and immune cell migratory capacity following natalizumab treatment.

Main Methods:

  • Blood samples were collected before and after natalizumab infusions.
  • Flow cytometry was used to analyze VLA-4 expression and immune cell subsets.
  • Immune cell migratory capacity and activation thresholds were evaluated.

Related Experiment Videos

Main Results:

  • Natalizumab partially reduced VLA-4 expression and migratory capacity of circulating immune cells.
  • Effects on immune cell subsets were differential and varied between patients.
  • The impact of natalizumab was not saturating or sustained throughout the monthly dosing interval.
  • Treatment modulated immune cell proliferative responses and activation thresholds.

Conclusions:

  • Natalizumab diminishes immune cell migratory capacity in MS patients.
  • Therapeutic effects are subset-specific, patient-specific, and not sustained over the dosing interval.
  • Monitoring immune cell parameters may be relevant for assessing natalizumab safety and efficacy.